Benjamine Liu
Benjamine Liu, Chief Executive Officer and Co-founder of Formation Bio since 2014, has revolutionized drug development by integrating AI and technology to streamline clinical trials and accelerate new therapies to patients. Under his leadership, Formation Bio has secured significant funding and forged key partnerships, including with OpenAI and Sanofi, to advance AI-driven drug discovery and development. His vision has positioned Formation Bio as a leader in the biotechnology sector, recognized for its innovative approach to making treatments more accessible.
Career Milestones
- Co-founded and became CEO of Formation Bio in 2014, transforming drug development through AI integration.
- Led Formation Bio to secure significant funding and partnerships with OpenAI and Sanofi.
- Earned a DPhil at Oxford University as a Rhodes Scholar, focusing on AI for neurodegenerative diseases.
- Received Yale's Alpheus Henry Snow Prize and was a Paul Mellon Fellow at Cambridge.
- Advises Harvard Business School's MS/MBA Biotech Program since 2021.
- His leadership continues to accelerate new therapies to patients through innovation and technology.
About Formation Bio
Formation Bio is a tech-driven pharmaceutical company that acquires clinical-stage drugs from other pharma and biotech companies to develop them more efficiently. It serves these companies and ultimately patients by accelerating access to new treatments. Its differentiator is a proprietary AI-powered platform that optimizes clinical drug development for faster trials and higher quality data.